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This paper reviews the incidence, pathogenetic mechanisms and management strategies of diabetes mellitus in
patients with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). It classifies
patients based on the aetiopathogenetic mechanisms, and proposes rational methods of management of the
condition, based on aetiopathogenesis and concomitant pharmacotherapy.
Introduction
Patients with human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS) are
increasing in number, partly due to improved screening,
earlier diagnosis, better methods of treatment, and
greater accessibility to, as well as acceptance of therapy.
Figures from the United Nations reveal that the total
number of patients with HIV is 33 million, with 2.7
million new infections in 2007 [1].
Improved methods of detection of HIV, earlier diagno-
sis, and better management have helped in improving
the survival of these patients. The availability of, and
access to, potent retroviral and anti-infective therapy
has translated into lesser acute morbidity and mortality,
and thus, a longer lifespan. This is turn, has meant an
increase in the chronic complications of HIV encoun-
tered in clinical practice [2]
.
HIV/AIDS patients, therefore, frequently present with
diabetes and metabolic complaints. As treatment of HIV
develops, and access to therapy improves, the incidence
of HIV-associated diabetes is bound to grow. An inter-
national cross-sectional study of 788 HIV-infected adults
recruited at 32 centers has studied the metabolic syn-
drome prevalence using International Diabetes Federa-
tion (IDF) and U.S. National Cholesterol Education
Program Adult Treatment Panel III (ATPIII) criteria,
relative to body composition (whole-body dual-energy
X-ray absorptiometry and abdominal computed tomo-
graphy), lipids, glycemic parameters, insulin resistance,
leptin, adiponectin, and C-reactive protein (CRP) [3]
.
T h ep r e v a l e n c eo fm e t a b o l i cs y n d r o m ew a s1 4 %( n =
114; 83 men) by IDF criteria and 18% (n = 139;
118 men) by ATPIII criteria. Half of the patients (49%)
exhibited two or more features of metabolic syndrome
but were not classified as having the syndrome because
they had normal or low waist circumferences or waist-
to-hip ratios. Metabolic syndrome was more common in
those currently receiving protease inhibitors (P =0 . 0 4 ) .
Type 2 diabetes prevalence was five- to ninefold higher
in those with metabolic syndrome [3].
In another study, the incidence of new-onset diabetes
in HIV-infected persons was significantly high. Over
130,151 person-years of follow-up (PYFU), in the Data
Collection on Adverse Events of Anti-HIV Drugs (D:A:
D) Study, diabetes was diagnosed in 744 patients (inci-
dence rate of 5.72 per 1,000 PYFU [95% CI 5.31-6.13]).
The incidence of diabetes increased with cumulative
exposure to combination ART. The strongest relation-
ship with diabetes was exposure to stavudine, while
treatment with zidovudine and didanosine was also
associated with an increased risk of diabetes [4].
Management of HIV/AIDS is gradually expanding to
include the chronic, and metabolic, complications of the
disease, and the adverse effects associated with its treat-
ments. The aim of this article is to review the manage-
ment strategies for diabetes in patients in HIV/AIDS,
while understanding the pathophysiologic mechanisms
predisposing to their condition.
Diabetes and HIV: Classification
Three subgroups of patients with diabetes and HIV can
be identified: Patients with preexisting diabetes who
contract HIV, those who are diagnosed to have diabetes
at onset of HIV infection, and others who develop
hyperglycemia after start of therapy. These subgroups
need to be managed differently, as the mechanisms of
metabolic dysregulation vary in them.
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diabetes as seen in the background population. Because
of their relatively younger age, HIV patients may have
lower incidence of preexisting diabetes when they get
infected. However, as they grow older, they may develop
diabetes in the normal course of events. Certain meta-
bolic factors related to HIV, and to HIV therapy, may
increase the incidence of diabetes among them.
These factors will be discussed in the following para-
graphs. This knowledge is of importance to treating
physicians, as it will help them plan their mode of
treatment.
Aetiopathogenesis
With a high prevalence of diabetes in the background
population, it stands to reason that the same predispos-
ing factors will operate in patients with HIV.
A p a r tf r o mt h i s ,h o w e v e r ,HIV patients present with
metabolic syndrome, altered glucose metabolism, dysli-
pidemia and lipodystrophy.
Many risk factors contribute to the development of
metabolic syndrome in such patients. These include
advancing age, male gender, longer duration of HIV
infection, low CD4 count, high viral burden, high body
mass index, greater waist circumference or waist- to-
hip ratio, lower socio economic class, and certain ethnic
backgrounds or culture [5,6]
Impaired glucose tolerance, and insulin resistance are
noted to precede weight loss in patients with HIV [5-9].
Insulin resistance, rather than insulin deficiency, is
usually implicated in the pathogenesis of diabetes in
HIV-infected patients. According to earlier reports, evi-
dence of islet cell autoimmunity, or beta cell destruction
has not been seen in HIV patients [10].
Autoimmune diabetes, however, has recently been
reported to develop in some HIV-infected patients after
immune restoration during HAART. Three Japanese
patients presenting with diabetes after receipt of
HAART have been shown to develop antibodies to glu-
tamic acid decarboxylase, at a time when CD4 counts
shot up suddenly. The postulate is that recovery of
immune function predisposes to autoimmune disease, in
the form of type 1 diabetes (T1DM) [11].
The type of diabetes associated with HIV may be clas-
sified as type 2 diabetes (T2DM), rather than T1DM, in
the vast majority of patients.
Concurrent use of opiates, however, may alter beta
cell function[12], while heroin addiction is associated
with insulin resistance. No specific mechanisms of
action have been proposed for these effects. No studies
have been reported on alpha-cell function in people
with concurrent HIV and diabetes.
HIV infection is linked with hepatitis C infection
(HCV), which is associated with insulin resistance and
diabetes, due to increased intrahepatic tumour necrosis
factor (TNF a) and hepatic steatosis[10]. These factors
increase the risk of diabetes in a patient suffering from
concurrent HIV and HCV infection. Persons with HCV
who are 40 years of age or older are greater than
3 times more likely to have diabetes than those of the
same age without HCV infection[13]. In a Korean study
of 1,117 patients with chronic viral hepatitis, 21% of
HCV-infected patients had a diagnosis of diabetes, com-
pared with 12% of patients infected with hepatitis B
virus [14]
HIV is also associated with various endocrine abnorm-
alities, including those of the growth hormone axis.
These include deficiency of growth hormone, as well as
growth hormone resistance. Growth hormone deficiency
may contribute to insulin resistance in HIV-infected
patients [15].
The increased accumulation of visceral fat, with wast-
ing of subcutaneous fat, noted in these patients, creates
higher levels of inflammatory cytokines such as TNF a.
This in turn leads to diabetes or impaired glucose toler-
ance by increasing insulin resistance [16].
HIV-infected subjects with metabolic syndrome show
disturbances in inflammation and adipokines: they have
higher CRP (5.5 ± 7.0 vs. 3.9 ± 6.0 mg/l, P <0 . 0 0 3 )a n d
leptin (9 ± 9 vs. 4 ± 6 ng/ml, P < 0.0001) and lower adi-
ponectin (12 ± 8 vs. 15 ± 10 μg/ml, P < 0.0001) levels.
This may contribute to the pathogenesis of diabetes[3].
Viral factors which contribute to diabetes risk are an
increase in viral burden of 0.5 log over a 6 month per-
iod, a lower CD4 count, and longer duration of HIV
infection [5]. In general, people with severe, long-stand-
ing HIV infection are more prone to developing
diabetes.
The above listed factors partly explain the pathogen-
esis of diabetes detected during the natural history of
HIV infection.
The major contributor to hyperglycemia in HIV/AIDS,
however, is iatrogenic. The past few decades have seen
remarkable improvement in the clinical outcome of HIV
patients, thanks to highly active antiretroviral therapy
(HAART). Benefits of HAART include suppression of
viral load, improvement in CD4 count, decrease in
opportunistic infections and length of hospital stay, and
reduction in mortality [17,18].
HAART however, has also lead to an increase in
metabolic dysfunction, including insulin resistance, dia-
betes dyslipidemia and lipodystrophy [12].
This constellation of abnormalities is also called anti-
retroviral-associated diabetes, and is consistent with the
clinical picture of T2DM, rather than T1DM [10].
A recent analysis has found that diabetes is four fold
more common is HIV-infected men exposed to highly
active anti retroviral therapy (HAART) than in HIV
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. HAART is based on the use of a
class of drugs known as protease inhibitors (PIs), which
have been used extensively as antiretroviral agents. The
various PIs used include atazanavir, darunavir, saquina-
vir and ritonavir.
PIs have been shown to increase insulin resistance and
reduce insulin secretion, by interfering with GLUT-4
mediated glucose transport. Risk factors for develop-
ment of diabetes with PI therapy include positive family
history of diabetes, weight gain, lipodystrophy, old age
and hepatitis C infection [20]. PIs interfere with cellular
retinoic acid-binding protein type 1 (CRABP 1) that
interacts with peroxisomal proliferator-activated recep-
tor (PPAR) g. Inhibition of PPAR-g promotes adipocyte
inflammation, release of free fatty acids and insulin
resistance [21]. Hyperglycemia resolves in almost all
patients when PIs are discontinued [21].
All PIs do not have the same metabolic effects. Indi-
navir induces insulin resistance with no effect on lipid
metabolism, whereas lopinavir and ritonavir increase
fasting triglycerides and free fatty acids, but do not
worsen insulin sensitivity. Indinavir and retonavir both
block GLUT -4, but no such effect is noted with
amprenavir, and atazanzvir. HIV-infected patients trea-
ted for 12 weeks with nelfinavir, indinavir, liponavir or
saquinavir, demonstrate alterations in first phase insu-
lin release with a 25% reduction in b-cell dysfunction
[20,21].
This implies that there is no class effect of PIs on dia-
betes, and that various PIs should be studied individually
with respect to their metabolic effects [21]. The thera-
peutic implication is that treating physicians should be
aware of the predominant mechanism of diabetes linked
to each drug, so that appropriate anti-diabetic therapy
can be chosen. For example, a patient with diabetes due
to nelfinavir, indinavir, liponavir or saquinavir therapy
will benefit more from insulin than from insulin sensiti-
zer therapy.
T h eo t h e rc l a s so fd r u g sw h i c hi su s e di st h en u c l e o -
side analogs (reverse transcriptase inhibitors) (NRTIs). It
was earlier felt that NRTIs were less likely to cause
metabolic abnormalities. A recent study, which analyzed
130 151 person years of exposure, however, has shown
that these drugs, too, increase the risk of diabetes [4].
The risk is highest with stavudine, but is also signifi-
cant with zidovudine and didanosine. Proposed mechan-
isms include insulin resistance, lipodystrophy, and
mitochondrial dysfunction [22]. These mechanisms may
be evident only in HIV-infected persons treated for long
periods of time with NRTIs [22]. This does not mean
that HAART should not be prescribed to patients with
HIV and diabetes. One should be aware of the adverse
metabolic effects of these drugs, and take proactive
steps to prevent and manage these.
It is postulated that PIs confer acute metabolic risks,
while NRTIs confer cumulative risks of diabetes in pre-
disposed, exposed persons. Exposure to a combination
of NRTI and indinavir (a PI) has been shown to be an
additional risk factor for onset of diabetes [22].
Anti-retroviral drugs are not the only iatrogenic cul-
prits in HIV-associated diabetes. Drugs used to manage
comorbid conditions associated with AIDS may also
cause diabetes. Pentamidine, which is used to prevent
and treat P. carinii associated pneumonia, can cause
b-cell toxicity, with acute hypoglycemia followed by later
diabetes. Factors associated with increased risk of hypo-
glycemia are longer and higher dosage of pentamidine, as
well as renal insufficiency. The group of patients which
progressed to diabetes had low C peptide levels, sugges-
tive of b- cell destruction [23,24]
. This mechanism of
action implies that insulin will be the only rational choice
of treatment in patients with pentamidine-induced dia-
betes. About 8% of all pentamidine-treated patients will
develop hypoglycemia [25] This is of importance because
P. carinii pneumonia is the most common index infection
at time of diagnosis of AIDS [26].
Megesterol acetate, which is used as an appetite sti-
mulant, predisposes to diabetes because of its intrinsic
glucocorticoid like activity, increased caloric intake and
weight gain [27]. Hypoglycemia has been noted to
resolve once megesterol is stopped, and to recur on
rechallenging.
Patients on HAART may also be predisposed to dia-
betes because of the improved nutritional status and
weight gain that accompanies effective treatment
of HIV.
Screening for Diabetes
Patients with HIV should be screened for diabetes at
diagnosis, at onset of HAART therapy, and three to six
months after HAART. While certain professional bodies
advise fasting blood glucose as a screening tool [28], the
predominant role of insulin resistance in the develop-
ment of the illness implies that postprandial glucose
values, or an oral glucose tolerance test, should also be
performed as part of screening procedures.
One may follow guidelines for the general population,
and screen all HIV patients at diagnosis and at regular
intervals, with both fasting and postprandial glucose
values. Venous samples should be taken for diagnosis,
rather than fingerprick values. Glucose challenge tests
may be indicated in select cases. A1c has not been
recommended as a diagnostic test in HIV/AIDS.
Strategies to Manage Hyperglycemia
Guidelines for management of diabetes in the OPD set
up have been discussed in detail elsewhere. However,
these do not focus on HIV-associated diabetes.
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ferent in HIV patients than in the general population.
The unique features of diabetes management in HIV are
listed and discussed below:
1. General Measures
Modification of risk factors such as hypertension, dysli-
pidemia, and platelet function should be done through
non-pharmacological and pharmacological methods, as
in non-HIV infected patients. Precipitating factors such
as tuberculosis should be searched for, and treated
aggressively. Concurrent sexually transmitted diseases,
pruritus vulvae, and balanoposthitis should be screened
for, and managed appropriately. A complete physical
examination of the genitalia is mandatory. Untreated
genito-urinary infection is a common cause of poorly
controlled hyperglycemia.
Dyslipidemia is common in HIV, and treatment guide-
lines are available to help practitioners handle this com-
plication [28]. Pravastatin and fluvastatin are safe to use
with ritonavir. Atorvastatin and rosuvastatin should be
used with caution, while simvastatin is contraindicated
in patients on this PI [29]. This is because of the com-
mon cytochrome P450 isoenzyme. pathways used for
metabolism
Hypertension, too, is a frequent comorbid condition.
The routinely used antihypertensives, such as angioten-
sin converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) may not be optimal choices in
patients with HIV [29]. Captopril has been associated
with Kaposi’s sarcoma, hepatotoxicity and neurotoxicity.
Enalapril is linked with muscle pain, weakness and diar-
rhoea. ARBs may compete with other drugs that are
metabolized by the cytochrome P450 isoenzyme.
2. Life Style Modification
Diet, physical activity/exercise and cessation of smoking
are as important in HIV-infected as in non infected per-
sons [30,31].
Weekly counseling by a dietician with main emphasis
on healthy eating, and limited emphasis on weight loss,
has been shown to reduce blood pressure, waist circum-
ference and HbA1c significantly [32], along with a
reduction in caloric intake and percentage of calories
from saturated fat, as well as increased fibre intake. On
the other hand, many patients of HIV are cachexic, and
need increased caloric intake to improve general health.
This caloric intake should be a balanced diet, following
the same proportions that non-HIV infected patients are
recommended.
Endurance and resistance exercise have been shown to
have positive effects on metabolic parameters in HIV
infected patients [33]. Similar results, including
decreased blood pressure, increased strength and
endurance, lower cholesterol and increased insulin sen-
sitivity [30,34] are seen with weight lifting and aerobic/
endurance exercise.
Smoking cessation is critical for optimal health.
Newer non nicotine replacement therapy should be
used in caution in HIV patients. Varenicline and bupro-
pion may interact with drugs metabolized by the cyto-
chrome P450 isoenzyme, e.g, ritonavir, efavirenz and
nelfinavir [35].
3. Psychosocial Support
While psychosocial support is an integral part of effec-
tive diabetes management, it is of utmost importance in
patients who have to handle the double stress of dia-
betes and HIV.
Strategies to support behaviour change need to be
individualized, culture- age - and gender - appropriate,
negotiable, flexible and dynamic. The WATER approach,
coined at Bharti Hospital, Karnal, India, is an effective
method of motivational interviewing [36]. WATER
stands for Welcome Warmly, Ask and Assess, Tell the
Truth, Explain it with Empathy, and Reassure and
encourage to Return. These five points encapsulate the
basic principles of diabetes/HIV counseling, and are an
easy method of teaching health care providers how to
deal with patients.
Coping skills training should be provided to all HIV
patients, and should focus on enhancing positive coping
strategies, confidence and self-esteem. The AEIOU
method is a simple and time-efficient way of doing so
[37]. AEIOU implies Ask and Assess coping skills;
Explain and Eliminate negative coping methods; Identify
and Internalize positive methods of coping; Observe on
an Ongoing basis for improvements; and Utilize as well
as Upgrade ones’ skills continuously.
4. Oral Anti Diabetic Drugs (OADs)
OADs are frequently used in patients with T2DM. The
patient with coexistent HIV infection, however, poses a
special challenge.
This patient is at greater risk of comorbidity such as
hepatitis C, tuberculosis or other opportunistic infec-
tions. He or she may have severe insulin resistance. The
number of concomitant medications is greater, leading
to an increased chance of drug interactions. Because of
impaired renal and hepatic function, the risk of adverse
events and drug toxicity may be higher. Cachexia and
impaired appetite may increase the risk of hypoglycemia.
Gastrointestinal infections and dysfunction may worsen
tolerability of various oral drugs, and alter their absorp-
tion [38,39].
One should therefore choose an OAD regime in
patients with diabetes and HIV with great care (Addi-
tional file 1).
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sons with T2DM, but should be used with caution
in HIV.
Though it improves insulin sensitivity, it may not be
well tolerated by cachexic patients. Metformin is more
likely to cause diarrhea than other drugs [40]
It is contraindicated in renal or hepatic dysfunction,
and may lead to metformin-associated lactic acidosis
(MALA). It should be avoided in combination with
drugs such as stavudine, which also increase the risk of
lactic acidosis[40]. Abacavir, lamivudine and tenofovir
are the least likely drugs to cause elevation of lactate
levels.
HIV patients on metformin should be educated about
the symptoms of lactic acidosis, including fatigue, weight
loss, nausea, abdominal pain, dyspnea, and arrhythmia.
Liver-related symptoms such as tender hepatomegaly,
edema, ascites and encephalopathy may occur, but jaun-
dice is uncommon [38].
Metformin should be avoided in patients with comor-
bid infection such as tuberculosis, weight loss, cachexia,
ketonuria and lipoatrophy. Further reductions in subcu-
taneous fat can occur with this drug [40]. This in turn,
may worsen lipodystrophy seen with HIV, and lead to a
deterioration in various metabolic parameters.
The thiazolidinediones have a mechanism of action
which should make them drugs of choice in HIV. The
possibility of a slight increase in subcutaneous fat makes
them the preferred drug class in patients with lipody-
strophy [28]. However, poor responses to peroxisome
proliferator-activated receptor-g agonists and fibrates
have been reported in randomized trials in HIV infected
patients with T2DM[41]. The drugs are contraindicated
in hepatic dysfunction and heart failure. They may cause
edema, increase cardiovascular morbidity, worsen osteo-
porosis, and decrease hematocrit. These side effects pre-
vent wide usage of these drugs in T2DM, as well as
HIV-associated diabetes.
Ritonavir and nelfinavir may reduce rosiglitazone con-
centrations because of a similar metabolic pathway [38].
Few drug interaction studies have been done between
antidiabetic drugs and antiretroviral molecules, but the
potential for these, and the frequent administration of
polypharmacy for other comorbid conditions, implies
that insulin is a safer alternative.
Insulin secretagogues such as repaglinide, and sulpho-
nylureas (glimepiride, gliclazide, glibenclamide) are safe,
but may not be effective in the face of severe insulin
resistance. However, amongst the OADs, they have a
faster onset of action, and may be used in appropriate
doses, provided there is no ketonuria. The glinides
address the defect in first phase insulin secretion that is
seen with certain PIs, and may be an appropriate choice
of OADs [38].
The newer class of OADs, the polypeptide protease
(IV) inhibitors, ie, saxagliptin, sitagliptin, and vildaglip-
tin, have not been studied in patients with HIV and dia-
betes. There is a theoretical risk of immunodeficiency
and exacerbation of infections [42] with these drugs,
however, which prevent them from being used as first
line drugs in HIV.
Effects similar to those seen in the general popula-
tion may be expected with incretin mimetics in
HIV-infected patients. Liraglutide has recently been
reported to improve various indices of insulin sensitiv-
ity, including HOMA-IR, blood pressure and weight,
apart from achieving effective hypoglycemic control
[43]. These properties may make it worthwhile to
study the effect of liraglutide and exenatide in HIV-
associated diabetes.
5. Insulin
Insulin is the drug of choice for management of dia-
betes with HIV. Insulin has an anabolic effect, is
known to reduce inflammatory markers such as TNF-
alpha, does not have any interactions with antiretro-
viral or other drugs, is not contraindicated with renal
or hepatic dysfunction, does not reduce appetite or
cause gastrointestinal side effects, can correct both
insulin deficiency and resistance when given in appro-
priate doses, and does not increase the risk of cardio-
vascular disease[44].
Insulin therapy should be initiated at the outset, using
basal bolus regime or premixed insulin. The American
Association of Clinical Endocrinologists recommends
the use of modern insulins or insulin analogues, as they
are more predictable in action, and cause less hypogly-
cemia. The use of traditional human insulins is discour-
aged [45].
Insulin requirements are high to begin with, and fall
after a few weeks, once glucotoxicity is corrected and
infection controlled. Insulin requirements may rise as
appetite returns to normal and caloric intake increases.
Sick patients should be tested for ketonuria [46]. Rapid
acting analogues such as aspart insulin may obviate the
need for admission in patients with ketonuria [47], and
are useful for critically ill patients as well [48].
An average patient will need 1.0 U/kg/day of insulin
initially, divided as 60% bolus and 40% basal insulin. In
a few weeks, the requirement will come down to 0.5
U/kg/day, and may be met by two or three equal doses
of premixed aspart/lispro [49]. Basal insulin is usually
not sufficient alone to meet insulin requirements in
severely infected patients with HIV/AIDS (personal
observation).
HIV-infected patients should be taught how to dispose
of lancets, glucose strips, insulin syringes, pens and nee-
dles, to prevent HIV transmission.
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PI-based regimes should be avoided in patients at high
risk of developing diabetes, e.g., those with a history of
gestational diabetes, a positive family history of diabetes,
or impaired glucose tolerance on screening. Indinavir
should be avoided, and replaced with less toxic drugs.
Structured treatment interruption should be avoided
as it increases the risk of death, opportunistic disease
[50], and myocardial infarction [51].
Patients should be counselled about the potential
risks, discomforts and benefits of HAART, and encour-
aged to follow a healthy lifestyle while monitoring glyce-
mia regularly.
Management of Pre-Existing Diabetes
Pre-existing T2DM may continue to be managed, after
diagnosis of HIV, with the same drug therapy that was
being used prior to detection of HIV. Patients should be
informed about the chances of worsening hyperglyce-
mia, and educated about the features of ketosis and lac-
tic acidosis. In case glycemic control deteriorates,
insulin should be initiated, rather than increasing dosage
or number of OADs.
Management of Diabetes Detected at Diagnosis
Patients diagnosed to have diabetes and HIV together
may be treated according to guidelines for non-
infected individuals. The initial drug of choice will
remain metformin, unless contraindicated or not toler-
ated. In such cases, it will be prudent to use insulin or
low dose meglitinides as a second line therapy. The
baseline A1c will determine the choice of therapy to a
large extent
Management of Diabetes Occurring After Haart
Patients developing diabetes after HAART may be trea-
ted with OADs, metformin being the first choice. How-
ever, control is usually suboptimal (personal experience).
Insulin is a better and safer choice, and may be tapered
or reduced once control is achieved.
Conclusion
The effective management of diabetes in HIV infected
patients requires a thorough understanding of pathophy-
siology and pharmacology. The choice should be based
on the aetiopathogenesis of the disease. Patients with
pre-existing diabetes should be counseled about a possi-
ble deterioration in metabolic function, and the chances
of drug interactions between OADs and HAART.
Patients who are detected to be diabetic at onset of
therapy or later, may benefit from insulin. Insulin is a
safe and effective method of treating all these patients,
irrespective of type of diabetes.
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